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Abstract

ADHD is the most commonly diagnosed Axis I mental health disorder in children with
prevalence estimates of 3% to 5% of US children. The preponderance of ADHD research has
focused on behavioral problems, while a much smaller proportion of research has focused on
cognitive aspects. The purpose of this study was to examine stimulant medication effects on
memory in children with ADHD. METHOD: Thirty-five children (26 males and 9 females) with
the diagnosis of ADHD (subtypes included predominately inattentive, predominately
hyperactive, and combined) were mostly obtained from local pediatric clinics. The Wide Range
Assessment of Memory and Learning, 2nd Edition (WRAML2) was administered along with the
Wechsler Abbreviated Scale of Intelligence (WASI) over 2 sessions, 1 of which the participants
were on their prescribed medication, and 1 of which was a placebo condition. Participants and
Examiner were blind to condition. CONCLUSION: Contrary to expectation, there was no
difference between participant performance when on medication vs. placebo for the WRAML2
subtests (Wilks λ = .66, F(15, 19) = .65, p > .05) or WASI subtests (Wilks λ = .81, F(4, 30) =
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1.71, p > .05). Therefore, stimulant medication had no demonstrable effect on memory
performance in children with ADHD. Implications of this finding were discussed.

iv

Effects of Medication on Memory

v

Acknowledgments
The completion of this tremendous undertaking would not have been possible without the
love, support, and sacrifice of those around me. I am eternally indebted to my wife Jeanni.
Without her love and patience I would not be where I’m at today. She has given more to me
than I could ever describe in a few short sentences; my thanks is not enough. To my sweet
daughters Lindsey and Macy; thank you for your smiles and constant reminders that my
dissertation pales in comparison to being a father. Thank you to my parents and family for their
continued support and encouragement throughout my academic career. I would also like to
extend my sincere thanks to my committee members, Kathleen Gathercoal, PhD and Robert
Buckler, MD. I owe a special thank you to my dissertation chair, Wayne Adams, PhD. His
willingness to dialogue and challenge me made this project better than I could have imagined.
His professional mentoring has meant a great deal to me and has yielded a polished and efficient
professional. I would also like to give a special thank you to my colleague and friend Scot
Burkhart. His continual support and sense of humor allowed me to persevere at my most
frustrated. Finally, thank you to all the parents and children who participated in this study.
You’ll never know how valuable you were to my academic success.

Effects of Medication on Memory

vi

Table of Contents
Approval Page .................................................................................................................................ii
Abstract...........................................................................................................................................iii
Acknowledgements ......................................................................................................................... v
List of Tables..................................................................................................................................ix
List of Figures.................................................................................................................................. x
Chapter 1: Introduction.................................................................................................................. 1
ADHD and Academic Performance .................................................................................... 4
Attention and Inhibition ...................................................................................................... 5
ADHD and Executive Functioning ..................................................................................... 7
ADHD and Memory ............................................................................................................ 9
ADHD and Medication...................................................................................................... 13
Chapter 2: Methods ..................................................................................................................... 18
Participants ........................................................................................................................ 18
DSM-IV Criteria for ADHD ............................................................................................. 18
Inattention.............................................................................................................. 18
Hyperactivity ......................................................................................................... 19
Impulsivity............................................................................................................. 20
American Psychiatric Association (DSM-IV-TR), 2000 .................................................. 21
Instruments ........................................................................................................................ 24
The Wide Range Assessment of Memory and Learning, 2nd ed. (WRAML2) ..... 24
Wechsler Abbreviated Scale of Intelligence (WASI) ........................................... 29

Effects of Medication on Memory

vii

Continuous Performance Test (CPT-II) ................................................................ 30
Procedure........................................................................................................................... 32
Chapter 3: Results........................................................................................................................ 39
Hypotheses ........................................................................................................................ 42
Hypothesis 1 .......................................................................................................... 42
Hypothesis 2 .......................................................................................................... 43
Hypothesis 3 .......................................................................................................... 43
Hypothesis 4 .......................................................................................................... 43
Hypothesis 5 .......................................................................................................... 44
Hypothesis 6 .......................................................................................................... 44
Hypothesis 7 .......................................................................................................... 44
Hypothesis 8 .......................................................................................................... 44
Hypothesis 9 .......................................................................................................... 45
Hypothesis 10 ........................................................................................................ 45
Hypothesis 11 ........................................................................................................ 45
Hypothesis 12 ........................................................................................................ 42
Hypothesis 13 ........................................................................................................ 46
Hypothesis 14 ........................................................................................................ 46
Hypothesis 15 ........................................................................................................ 46
Hypothesis 16 ........................................................................................................ 47
Hypothesis 17 ........................................................................................................ 47
Hypothesis 18 ........................................................................................................ 48

Effects of Medication on Memory

viii

Hypothesis 19 ........................................................................................................ 48
Chapter 4: Discussion.................................................................................................................. 49
Limitations......................................................................................................................... 52
Future Directions ............................................................................................................... 53
References ..................................................................................................................................... 54
Appendix A

ADHD Questionnaire ............................................................................................ 66

Appendix B

Participation Flyer ................................................................................................. 69

Appendix C

Consent Form ........................................................................................................ 71

Appendix D

Background Information ....................................................................................... 73

Appendix E

ADHD Symptom History ...................................................................................... 76

Appendix F

Curriculum Vita………………………………………………………………….78

Effects of Medication on Memory

ix

List of Tables
Table1

Frequency Distributions of Demographic Variable .................................................... 22

Table 2

Frequency Distributions of ADHD Profile.................................................................. 23

Table 3

Person and Item Separation Reliabilities for WRAML2 Subtests .............................. 26

Table 4

WRAML2 Optional, Delay Recall, and Recognition Subtests ................................... 28

Table 5

Guidelines for Interpreting CPT-II T Scores and Percentiles ..................................... 31

Table 6

Activities Associated with Each Testing Session........................................................ 33

Table 7

Content of Each WASI Subtest Groupings that was Administered on
Medication and Placebo .............................................................................................. 35

Table 8

Content of Each WRAML2 Subtest Groupings that was Administered
on Medication and Placebo ......................................................................................... 35

Table 9

ADHD Medications, Half-lives, Peak Action, and Duration of Action...................... 37

Table 10 Performance in Medication and Placebo Conditions .................................................. 40

Effects of Medication on Memory

x

List of Figures
Figure 1

The three core WRAML2 indexes and their contributing subtests ............................. 25

Figure 2

The WASI Full Scale IQ and its contributing subtests................................................ 29

Effects of Medication on Memory

1

Chapter 1

Introduction

“For over 20 years, Attention Deficit Hyperactivity Disorder (ADHD) has been viewed
as comprising three primary symptoms, these being poor sustained attention, impulsiveness, and
hyperactivity” (Barkley, 1997a, p. 65). Difficulties in these three areas are often broadly
classified as difficulties with executive functioning. Executive functioning has been defined as
the capacities to engage in independent, purposive, and goal-directed behavior (Busch et al.,
2005). These higher-order processes enable us to incorporate feedback and make behavioral
adjustments in accordance with environmental demands. Other abilities subsumed under the
broad category of executive functioning include attention, planning, organization, initiation, selfmonitoring, response inhibition, and generative behavior (Busch et al., 2005). Executive
functioning abilities are considered to be critically important for complex human behavior, and
their breakdown is thought to commonly result in behavioral or psychiatric impairment (Fisher,
Barkley, Smallish, & Fletcher, 2005).
The topic of Attention Deficit Hyperactivity Disorder (ADHD) has been significantly
researched. In a simple search of PsychINFO for the terms ADHD from 1998 to the present,
there were over 6,000 articles that were found. With the abundance of information concerning
ADHD it is difficult to cover all of the research that has been generated, however the most
salient research is summarized throughout this chapter.
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ADHD is generally considered a lifelong disorder that is not solely a function of a single
environmental stressor. As a result, the Diagnostic and Statistical Manual of Mental Disorders –
IV (DSM-IV; American Psychiatric Association, 2000) specifies that ADHD symptoms must be
present early in childhood, must continue for an extensive period of time, and must be displayed
in more than one setting. There is currently no compelling evidence that ADHD in adolescents
is qualitatively different from the disorder in children, or adults for that matter (Barkley, 2004).
Critical in the classification of ADHD is the presence of several subtypes. Based on the two core
symptom clusters, the DSM-IV defines three subtypes of ADHD: a primarily hyperactiveimpulsive type, a primarily inattentive type, and a combined type (Lahey, et al., 1994).
Specifically, those children with the problems of inattention without high rates of impulsivity
and hyperactivity tend to show fewer conduct problems and less peer rejection, and are more
anxious and shy than those children who are also impulsive and hyperactive. The inattentive
subtype also “mainly involve students with academic impairment” (McCormick, 2003, p. 621).
The hyperactive and inattentive subtypes may also show differences in the types of attentional
processes that are deficient, and the inattentive type shows a different response curve to
stimulant medication (Barkley, DuPaul, & McMurray, 1991). The inattentive and distractible
behavior distinguishes ADHD from learning disabilities or other psychiatric disorders and does
not appear to be a function of the other disorders often comorbid with ADHD (anxiety,
depression, or oppositional and conduct problems; Barkley, Edwards, Laneri, Fletcher, &
Metevia, 2001a). A study by O’Driscoll et al. (2005) found that children with ADHD combined
subtype displayed more difficulties on tasks of executive functioning than children with ADHD
inattentive subtype.
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ADHD is the most commonly diagnosed Axis I mental disorder in children (Barkley,
1997b). Prevalence estimates vary widely as a function of diagnostic criteria used, but
reasonable estimates suggest that 3% to 5% of children nationwide are affected (Barkley,
1997b). Because ADHD accounts for a large proportion of all referrals for pediatric mental
health services, at great economic and emotional expense, the development of effective
treatments cross the childhood and adolescent years is essential (Hibbs & Jensen, 2005)
Although deficits in attentional abilities and other areas of cognitive functioning are
extremely problematic for children with ADHD, much of the research on the disorder has
focused on the behavioral problems and the perceived accompanying social disruptions
associated with it (DeShazo, Klinger, Lyman, Bush, & Hawkins, 2000). This leaves minimal
research regarding the core cognitive and memory impairments associated with the disorder.
“Cognitive domains such as verbal working memory, internalized speech, emotional self-control,
and cross temporal organization of behavior become progressively more elaborate in adolescents
and consequently may be more affected by the disorder than they were in childhood” (Barkley,
2004, p. 40). Many studies that have investigated the cognitive abilities of children with ADHD
have promoted the theory that the disorder involves frontal lobe dysfunction (Barkley, 1997b).
Neuropsychological research has suggested that certain regions of the brain may be
implicated in the disorder. Deshazo, Klinger, Lyman, Bush, and Hawkins (2000) found that the
performance of boys with ADHD on visual cueing tasks was not impaired relative to controls,
whereas the performance of the same boys with ADHD on a continuous performance test was
significantly impaired. The results suggest dissociation between selective and sustained attention
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abilities in children with ADHD and implicate the frontal lobe region as a specific area
associated with the impairment.
Impulsivity and inattention are the most reported symptoms of ADHD, however the poor
performance of children with ADHD on cognitive tasks cannot be explained exclusively by
inhibitory or attention control deficits (Shue & Douglas, 1992), suggesting that this impaired
performance may be representative of a higher order cognitive deficit. Research by Pennington
and Ozonoff (1996) suggested that children with ADHD may demonstrate difficulties in higher
order executive functioning processes such as planning, organization, and problem-solving
ability, while inattention and impulsivity may be secondary to these more global deficits. Since
ADHD involves deficits in global functions, then impairments in attentional processes and
impulse control would also be expected.
ADHD and Academic Performance
Children with ADHD are traditionally academic underachievers, a problem that appears
to be distinct to ADHD when compared to other disruptive behavior disorders, such as conduct
disorder (Frick et al., 1991). Frick and Lahey (1991) found that as many as 30% of children with
ADHD do not achieve academically at the level predicted by their age or IQ. Although this
finding may be interpreted as a problematic behavior which then interferes with academic
achievement, it may also be that children with ADHD have specific cognitive impairments that
hinder learning (Deshazo, 2001).
Children whose, “primary difficulties are with inattention more closely resemble children
with learning disabilities in their academic difficulties and associated behavioral difficulties”
(Shelton & Barkley, 1994, p. 31). The percentage of children experiencing some delay in the
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onset of talking may be somewhat higher for children with ADHD (6% - 35%) than for those
without ADHD (2% - 5. 5%; Shelton & Barkley, 1994). While not all children may have deficits
in language functioning, the language difficulties that some children with ADHD encounter may
be due to their difficulties with higher order cognitive processes. Depending on the definition,
approximately 25% to 50% of the children with ADHD will have at least one type of learning
disability, either in math, reading, or spelling (Shelton & Barkley, 1994).
Research has suggested that deficits in problem-solving and other cognitive processes are
likely linked with the poor academic performance associated with ADHD (McCormick, 2003).
For example, in addition to slower computational performance in mathematics, which may be
behavioral, children with ADHD also have been shown to score lower on measures of their
problem-solving ability in conceptual math (Zentall, Smith, Lee, & Wieczorek, 1994).
Specifying these cognitive impairments and their relation to academic achievement is still
unknown, however important to begin the subsequent process of identifying the possible causes
of underachievement in children with ADHD.
Attention and Inhibition
Attention represents a multidimensional construct. The dimensions impaired in ADHD
reflect an inability to sustain attention or persist at tasks, remember and follow through on rules
and instructions, and resist distractions while doing so (Bates, Mathias, & Crawford, 2001). By
adolescence, this dimension more likely reflects problems with working memory than poor
attention (Seguin, Boulerice, Harden, Tremblay, & Pihl, 1999). These difficulties can be more
broadly explained by four executive functions: operation of working memory; internalization of
self-directed speech; controlling mood, motivation and arousal; and reconstitution (the ability to
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break down and recombine behaviors; Bates, Mathias, & Crawford, 2001). These actions are all
important because they permit self-regulation in an individual. The attention and regulation
given to these concepts is often minimal in children and adolescents with ADHD.
As with attention, inhibition is a multidimensional construct. The problems with
inhibition seen in ADHD seem to involve voluntary or executive inhibition of proponent
responses. More specifically, teens with ADHD manifest difficulties with restlessness, less
ability to stay seated when required, talking excessively, acting impulsively, and interrupting
others’ activities (Nigg, 2001). In particular, delaying gratification and valuing future over
immediate rewards is difficult for the adolescent with ADHD. These inhibitory deficits extend
from emotional reactions to provocative social situations and to less tolerance for, and inhibition
of, frustration (Barkley, Edwards, Laneri, Fletcher, & Metevia, 2001b).
Recent research shows that the problems with inhibition are first identified (at age 3-4
years) in the hyperactive behavior of preschool children. These symptoms are then compounded
by an increase in those related to inattention over the next few years (by age 5-7 years). The
symptoms related to sluggish cognitive tempo that characterize the predominantly inattentive
subtype arise even later (ages 8-10; Hart, Lahey, Loeber, Applegate, & Frick, 1995). Whereas
the symptoms of hyperactivity decline by adolescence, inhibitory problems remain as evidenced
by difficulties with self-control, disregard for the consequences of one’s impulsive actions, and a
diminished valuing of future goals over immediate gratification (Hart et al., 1995).
It is important to note that it has not been consistently established that a diagnosis of
ADHD predicts deficient inhibitory control after controlling for various demographic factors
such as age and socioeconomic status. Second, tests purportedly measuring impulsivity assess
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additional cognitive factors, thereby precluding identification of the specific problematic
psychological processes for children with ADHD. Children with ADHD may perform worse on
these tasks due to an aversion to long delays, motivational problems, or problems adjusting to
different instructions rather than because of poor inhibitory control (Stevens, Quittner,
Zuckerman, & Moore, 2002).
ADHD and Executive Functioning
The conceptualization of ADHD as deficits in executive functioning has primarily been
supported by neurological and neuropsychological research. For example, research comparing
the neuroanatomy of children with and without ADHD show that children with the disorder have
decreased blood flow to the frontal lobes (Grodzinsky & Diamond, 1992). Magnetic resonance
imaging (MRI) scans have revealed that non-ADHD children have slightly larger right frontal
lobes than left; however, children with ADHD tend to lack this asymmetry, which may explain
their deficits in sustained attention, a process associated with the right frontal lobe (Hynd,
Semrud-Clikeman, Lorys, Novey, & Eliopulas, 1991). Further evidence for executive
functioning deficits in ADHD are illustrated by case studies of patients with frontal lesions.
These patients often display the hallmark behavioral symptoms of ADHD such as hyperactivity,
distractibility, and impulsivity. Thus, several researchers have hypothesized that the behavioral
symptoms of ADHD are linked to executive functioning deficits (Barkley, 1997b).
One key aspect of executive functioning that is important in self-regulation is working
memory (Chelonis et al., 2002). Working memory is the capacity to hold information in the
mind and use it to guide behavior, particularly across time and toward future goals. According to
Barkley (1997b), poor behavioral inhibition, as is seen in children with ADHD, should have
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resultant deficits in working memory. This hypothesis is in agreement with several proposed
models of working memory that suggest attention to a stimulus that is to be remembered is the
determinant of success on memory tasks. Research has shown that children with ADHD perform
poorly on tasks of working memory, including repetition of digits forwards and backwards,
mental arithmetic, the Freedom of Distractibility Scale of the Wechsler Intelligence Scale for
Children (WISC-III), and the Tower of Hanoi compared to non-ADHD control children (West,
Houghton, Douglas, & Whiting, 2002).
Executive functions are distinct from other mental functions such as sensation,
perception, or memory. There is, however, considerable overlap with domains such as attention,
reasoning, and problem solving and with certain components of learning and memory
(Biederman et al., 2004). While some research does indicate that deficits in executive
functioning are regularly found, after a review of the research literature, Halperin & Schulz
(2006) found that, “at the group level executive functioning measures do not appear to have the
sensitivity or specificity to adequately classify most individuals with ADHD relative to normal
controls.” Halperin and Schulz (2006, p. 562) go on to say, the specificity of deficits to inhibitory
control or executive functions is unlikely because children and adults with ADHD have
repeatedly been found to differ from controls on a wide array of ‘non-executive’ cognitive
functions such as motor coordination, perception, language, visuomotor integration, and learning
and memory. (p. 563).
Kempton et al. (1999) found that non-medicated ADHD children were impaired on tasks
of executive functioning, including planning ability, movement time, attentional set shifting and
spatial working memory. These cognitive impairments however, did not occur in medicated
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children with ADHD, possibly suggesting that stimulant medication normalizes executive
functioning in ADHD.
ADHD and Memory
Cognitive functions that are affected in ADHD also comprise memory processes (Krauel
et al., 2007). Recent imaging studies have revealed that ADHD patients show less activation in
prefrontal areas during working memory tasks than healthy subjects (Schweitzer et al., 2000).
Schon, Hasselmo, Lopresti, Tricarico, and Stern (2004) demonstrated that functional anatomic
overlap occurs between active maintenance of object information in working memory and
successful encoding into long-term memory in the prefrontal cortex and the limbic system.
Specific memory deficits associated with ADHD have become better understood in recent
studies, which tend to show deficits only for tasks that depend on more complex, organizational
components of memory (Kaplan, Dewey, Crawford, & Fisher, 1998). Implicit and explicit
memory are two forms of memory that have often been contrasted with one another in other
clinical and developmental contexts, but implicit memory has not been well-studied in ADHD
(Aloisi, McKone, & Heubeck, 2004). Implicit memory refers to an influence or facilitation in
performance based on some previous experience in the absence of conscious recollection,
whereas explicit memory depends on conscious recollection (Burden & Mitchell, 2005).
Karatekin (2004) found that children with ADHD do not appear to have generalized
impairments in working memory, but they may be more prone to specific impairments in
working memory related to the ability to divide attention during tasks. This finding supports
suggestions that inconsistencies for finding memory differences in ADHD across the literature
may stem from a lack of specificity when characterizing memory deficits (Kaplan et al., 1998).
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Mealer, Morgan, and Luscomb (1996) found that children with ADHD had more memory
difficulties than their peers without ADHD on general memory, but more particularly on visual
memory and verbal learning, which are more dependent on active processing and storage of
information during the test session. By contrast, the ADHD group performed comparably to the
non-ADHD group when stimuli were readily visible during testing (e.g., picture completion,
picture arrangement.
In 2002, Stevens et al. found that children with ADHD performed poorer than children
without the disorder on working memory task. Children in the ADHD group were able to recall
fewer digits than children in the control group when both processing and storing information
were required. This finding is consistent with previous research indicating that working memory
is a major problem for these children (Mariani & Barkley, 1997). These results carry additional
significance because performance on the working memory task was not dependent on skills
acquired in specific academic domains, such as reading. Other researchers have also begun to
disentangle impairments in working memory from difficulties with reading or mathematical
operations (Mariani & Barkley, 1997).
Memory storage and retrieval have been related to executive functioning and children
with ADHD have been found to perform poorly on verbal fluency and pair associate tasks
(Hoeppner et al., 1997). Kaplan et al., (1998) found that when tested using the Wide Range
Assessment of Memory and Learning (WRAML), a test of memory in both the verbal and nonverbal domains, children with ADHD scored lower than age-matched controls on the General
Memory Index, which taps both immediate and delayed recall. Dewey et al. (2001) found that
using the WRAML2 increased diagnostic acuity when used with other assessment measures.
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Sergeant (2000) propose that memory is not an independent cognitive process. Instead, memory
function is highly related to allocation of attention and other executive functions related to
utilization of efficient rehearsal strategies, as well as activation and motivation.
The WRAML subtests all require some type of “on the spot” learning and processing that
would be more susceptible to disruption by attention problems than would be other types of
cognitive activity (Mealer, Morgan, & Luscomb, 1996). This 1996 study found that participants
with ADHD scored significantly lower than the non-ADHD control group on the WRAML,
including the General Memory Index, Visual Memory Index, and Learning Index, with the
Learning Index displaying the greatest different between groups. At the subtest level, the most
noticeable differences took place on the Finger Windows and Verbal Learning; Visual Learning,
and Sound Symbol were very close to reaching significance.
Children with ADHD performed poorer on the WRAML, consistently reporting lower
scores on subtests including Finger Windows, Verbal Learning, Sentence Memory, and Number
Letter Memory (Kaplan et al., 1998). All of these subtests require immediate processing and
recall of novel material. The fact that these subtests assess verbal and non-verbal working
memory is of interest because other studies have shown that children with ADHD generally have
less difficulty processing and retaining information in the non-verbal domain (Webster, Hall,
Brown, & Bolen, 1996). It is unclear if the performance of children with ADHD on these tasks
is due to deficits in working memory or due to more global deficits. The subtests that seem to
cluster around attention and concentration are Number Letter Memory, Sentence Memory and
Finger Windows, the same subtests are also associated with working memory (Kaplan et al.,
1998). Attentional resources must be allocated to prolonging stimuli within working memory. If
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attention is drawn away from stimuli in working memory, the representation may decay before
rehearsal strategies allow for a more lasting memory trace to be created. Therefore, attentional
processes are integral to working memory functioning.
Memory tasks that are usually selected for psychopharmacological studies are tests such
as Pair Associate Learning, Delayed Matching to Sample, or simple recognition tasks for words
or figures (Frazier, Demaree, & Youngstrom, 2004). These tests, however, do not permit a
careful dissection of the memory process into its several components. The demonstration of a
positive stimulant effect on such tests can be interpreted simply in terms of an initial encoding
process effect, and it is this component that would be predicted to improve if stimulant memory
effects were mediated by simple attentional change or some other, indirect mechanism (Frazier et
al., 2004). Improvement in learning in the absence of change in immediate recall or span of
apprehension would suggest a drug effect on the storage process and/or the efficiency with which
information in retrieved (Evans, Gualtieri, & Amara, 1986). The memory tests above do not
discriminate these important factors; however, the WRAML2 incorporates this type of learning
and memory.
Other cognitive deficits would also give the appearance of reduced working memory
capacity. In particular, children with ADHD appear to have difficulty applying executive
functions to manipulate information within the working memory buffer. For example, children
and adults with ADHD appear to have more difficulty with memory updating, which is
selectively removing information from the working memory buffer to make room for new
information (Roodenrys, Koloski, & Grainger, 2001). This would, in effect, limit the working
memory capacity by taking up space with information bits that are no longer relevant.
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Experimental evidence suggests that the capacity of working memory in children with
ADHD is intact and that deficits in working memory function are more related to deficits in the
attentional/executive function components modulating the function of working memory
(Deshazo, 2001). This component of the memory system can accommodate approximately seven
individual bits of information at a time. Once a stimulus has entered the working memory store,
it begins to decay after approximately 30 seconds unless its memory trace is prolonged by
utilizing a mnemonic or rehearsal strategy (Roodenrys et al., 2001). Barkley (1997b) has
proposed that children with ADHD have difficulty with this prolongation process. Mehta,
Goodyer, and Sahakian (2004) found that methylphenidate improved performance on tasks of
working memory, visual search, and attentional-set shifting.
ADHD and Medication
Stimulant medication, particularly methylphenidate (MPH), is the most common
treatment for the management of ADHD. Studies estimate that 2.8% of elementary school-aged
children are taking medication for the management of ADHD with stimulants representing 99%
of the medications prescribed (Goldman, Genel, Bezman, & Slanetz, 1998). Several hundred
control studies have been conducted on MPH and support its effectiveness in the management of
major symptoms of ADHD (Barkley, DuPaul, & Conner, 1999). Research has suggested that
between 72% and 94% of children with ADHD respond positively to a single stimulant when
multiple doses are tried (Barkley, Conner, & Kwasnik, 2000). Nevertheless, there is substantial
inter-individual variability in drug response. Some children respond best at the lowest dose of
(2.5 – 5 mg) and deteriorate in their behavior with increasing dosage, while others show a peak
response at the highest dose (Rapport, DuPaul, Stoner, & Jones, 1986). Still others seem to show
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a curvilinear type of response with optimal responding occurring in the middle dose ranges
(Barkley et al., 2000). Moreover, 25% (or perhaps more depending on the study) of ADHD
children placed on a single stimulant medication, such as MPH, may show no positive response
at all, and 3-5% may have an adverse behavioral reaction (Rapport, Donney, DuPaul, & Gardner,
1994). Moreover, research on the use of psychostimulants in patients with ADHD without
hyperactivity showed a high rate of non-responders and no evidence of long term effects on
academic achievement and learning. It is not clear whether these results apply to patients with
predominately inattentive ADHD (McCormick, 2003).
The positive effects of MPH on attention and social behavior have been demonstrated
through teacher ratings, parent report, direct observation of classroom behavior, and clinic based
test of attention and impulse control (DuPaul, Anastopoulos, Kwasnik, Barkley, & McMurray,
1996). Methylphenidate is a stimulant drug related to amphetamine that acts to increase the
synaptic concentration of dopamine and noradrenaline (catecholamines) by blocking their
reuptake (Seeman & Madras, 1998). “Drug-related improvements also occur in other domains of
behavior, including aggression, handwriting, academic productivity and accuracy, persistence of
effort, working memory, peer relations, emotional control, and participation in sports” (Barkley,
2004).
Although neuropsychological studies of ADHD have consistently found impairments on
tests of executive function, there is still debate about the precise nature of such impairments
(Pennington & Ozonoa, 1996). For example, some studies using the Wisconsin Card Sorting
Test (WCST) have reported deficits in attentional set shifting in children with ADHD
(Gorenstein, Mammato & Sandy, 1989) while others have found no such impairments
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(Grodzinsky & Diamond, 1992). In addition, while studies of ADHD report poor performance
on measures of impulsivity or response inhibition on the Continuous Performance Test (CPT)
(Corkum & Siegel, 1993), on the Go-No-Go test (Shue & Douglas, 1992) and on time slowness
for Trails B (Shue & Douglas, 1992), others found no impairments on these tests (Grodzinsky &
Diamond, 1992). Furthermore, some researchers have reported impairments of visuospatial
processing (Grodzinsky & Diamond, 1992) while others have found no impairments in these
functions (Korkman & Pesonen, 1994). Finally, two studies have found impairments in planning
ability, measured with the Tower of Hanoi task and the Wisconsin Card Sorting Test (WCST)
(Weyandt & Willis, 1994). However, in ADHD, stimulant medication has been found to
improve performance on tests of executive function, especially when they are highly structured
measures of attention or vigilance such as reaction time or continuous performance tests (Mehta
et al., 2000). These paradoxical findings suggest that children with ADHD may require “overfocusing and perseveration” to perform within normal limits on tests which require sustained and
organized effort.
Spencer et al. (1996) reported that randomized controlled short term (less than 12 weeks)
trials reported improvement in about 65–75% ADHD patients on MPH versus 5–35% on
placebo. Historically, one of the main drawbacks of the immediate release forms of MPH was
the abbreviated duration of action. Due to its short term action, MPH had to be administered two
to three times daily. This constraint necessitated administering the medication during the school
which potentially created problems with peers and may have increased medication noncompliance (Deshazo, 2001).
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Longer acting MPH has been designed to overcome the drawbacks of short acting MPH.
The Ritalin-Slow Release (SR) represented an attempt for increasing MPH’s duration of action.
However, Ritalin-SR may have been less efficacious in a number of ways (Novartis, 2006). In
one study the SR preparation was noted to have slower onset of therapeutic action than the
immediate release form of MPH (Pelham, Sturges, & Hoza, 1987). Swanson et al. (1999) noted
a loss in its initial effectiveness during the afternoon rating periods. Explanations underlying
SR’s diminished effectiveness may be attributed to a number of pharmacokinetic factors which
included the delayed release of MPH, the lack of a steep absorption-phase and a flattened plasma
curve concentration after the establishment of peak concentrations (Birmaher, Greenhill, Cooper,
Fried, & Maminski, 1989). Northup, Gulley, Edwards, and Fountain (2001) found results
indicating that there is not necessarily any particular dose-response relationship between
disruptive behavior and academic performance at the individual level. The optimal dose for
behavior change may have minimal, or even a detrimental, influence on the child’s cognition or
learning (Hoeppner et al., 1997), or may result in adverse side effects at higher doses, such as the
“zombie effect,” characterized by affective blunting, dysphoria, and social withdrawal (Teeter &
Semrud-Clikeman, 1995).
Since ADHD medication is taken orally, absorption and distribution occur more slowly
and the peak onset of drug action is usually around one hour (Julien, 2001). Just as the rates of
absorption and distribution of a drug impact the onset and peak of a drug’s behavioral effects, the
half-life of a drug is also correlated with the duration of behavioral effects. The drug’s half-life
generally refers to the amount of time required to eliminate half of a drug from the body (Julien,

Effects of Medication on Memory

17

2001). There is some variance with respect to the half-lives and subsequent durations of action
of the drugs commonly used to treat ADHD.
Another question with respect to timing has to do with the frequency of changing
conditions. Most traditional clinical trials that have used rating scales as endpoints rely on no
sooner than weekly phase changes without repeating conditions (Evans et al., 1986). Other
studies, however, have evaluated the effects of different doses of medication by changing doses
on a daily basis and repeating conditions (Northup, Fusilier, Swanson, Roane, & Borrero, 1997).
Unfortunately, the literature offers little guidance as to which of these approaches is more
advantageous. Given the pharmacokinetic profiles of the commonly used medications, there is
no pharmacological reason why different doses or even drugs could not be evaluated in a fairly
rapid fashion, perhaps even daily (Deshazo, 2001). It is likely that the outcome measures
selected will influence, to some degree, the rapidity with which dose changes can be evaluated.
Standardized rating scales and general clinical impressions which are not necessarily anchored to
quantifiable changes in behavior may require more time for the raters to integrate judgments
across time, whereas direct observation may be assessed in a more rapid fashion (Kollins, 2004).
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Chapter 2

Methods
Participants
The sample consisted of 35 children. Participants satisfied a traditional DSM-IV
diagnosis for ADHD and were taking prescribed medication for this condition (see DSM-IV
criteria below). Diagnoses were made by professionals including pediatricians, master’s level
mental health therapists, and nurse practitioners. Diagnoses were verified by the author using a
symptom checklist based on DSM-IV criteria (see Appendix A). Forty-one participants
responded to the study; 6 were disqualified from the study because they were not taking
prescribed medication for ADHD.
DSM-IV Criteria for ADHD
A.

Either 1 or 2:

1.

Six or more of the following symptoms of inattention have persisted for at least six
months to a degree that is maladaptive and inconsistent with developmental level:
Inattention.
a) Often fails to give close attention to details or makes careless mistakes in schoolwork,
work, or other activities.
b) Often has difficulty sustaining attention in tasks or play activities.
c) Often does not seem to listen when spoken to directly.
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d) Often does not follow through on instructions and fails to finish schoolwork, chores,
or duties in the workplace (not due to oppositional behavior or failure to understand
instructions).
e) Often has difficulty organizing tasks and activities.
f) Often avoids, dislikes, or reluctant to engage in tasks that require sustained mental
effort (such as schoolwork or homework).
g) Often loses things necessary for tasks and activities (e.g. toys, school assignments,
pencils, books, or tools).
h) Is often easily distracted by extraneous stimuli.
i) Is often forgetful in daily activities.
2.

Six or more of the following symptoms of hyperactivity-impulsivity have persisted for
at least six months to a degree that is maladaptive and inconsistent with developmental
level:
Hyperactivity.
a) Often fidgets with hands or feet or squirms in seat.
b) Often leaves seat in classroom or in other situations in which remaining seated is
expected.
c) Often runs about or climbs excessively in situations in which it is inappropriate (in
adolescents or adults, may be limited to subjective feelings of restlessness).
d) Often has difficulty playing or engaging in leisure activities quietly.
e) Is often "on the go" or often acts as if "driven by a motor".
f) Often talks excessively.
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Impulsivity.
g) Often blurts out answers before questions have been completed.
h) Often has trouble awaiting turn.
i) Often interrupts or intrudes on others (e.g., butts into conversations or games).
B.

Some hyperactive-impulsive symptoms that cause impairment were present before age 7

years.
C.

Some impairment from the symptoms is present in two or more settings (e.g. at

school/work and at home).
D.

There must be clear evidence of significant impairment in social, school, or work

functioning.
E.

The symptoms do not happen only during the course of a Pervasive Developmental

Disorder, Schizophrenia, or other Psychotic Disorder. The symptoms are not better accounted
for by another mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or
a Personality Disorder).
Based on these criteria, three types of ADHD are identified:
1.

ADHD, Combined Type: if both criteria A1 and B1 are met for the past 6 months.

2.

ADHD, Predominantly Inattentive Type: if criterion A1 is met but criterion B1 is not met
for the past six months.

3.

ADHD, Predominantly Hyperactive-Impulsive Type: if Criterion B1 is met but Criterion
A1 is not met for the past six months.
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American Psychiatric Association (DSM-IV-TR), 2000
Participants were required to be between the ages of 9 and 12-years. The age range was
restricted to 9-12 due to the significant cognitive changes that occur between the ages of 5-8, and
the significant biological changes that occurs after the age of 12 (primarily for males). This
design was utilized to limit the possible noise a broad age range may have added to the study.
The children were recruited from Tigard, OR and surrounding communities through
recommendations from pediatricians, nurse practioners and other mental health providers. The
providers presented the participants with a flyer from the author, which briefly explained the
study and how to contact the author in order to participate (Appendix B).
The inclusionary criteria for participants included: (a) English as a primary language; (b)
meeting the diagnostic criteria for Attention Deficit Hyperactivity Disorder as defined by the
DSM-IV (see criteria above). The child may present with any subtype of ADHD including:
hyperactivity/impulsivity, inattention, or combined type; (c) taking prescribed medication for
ADHD symptoms for at least three months with minimal side effects as reported by parent and
child; (d) confirmation from the parent that their child may discontinue the use of his/her
stimulant medication for a period of at least 72 hours; (e) having not been diagnosed with a
significant neurological disorder such as autism, epilepsy, cerebral palsy, or recent head injury
with any loss of consciousness.
Due to the limited ethnic diversity of Tigard and the surrounding area, the majority of the
participants were Caucasian. However, there is no reason to expect ethnicity to be a relevant
variable in this study, as the primary measure has shown no significant differences between
principal ethnic groups (Sheslow & Adams, 2003). The demographic characteristics of age,
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gender, and ethnicity of the children who participated are displayed in Table 1. The average age
of participants was 11.0 (SD = 1.00, Skewness = -.749, Kurtosis = -.406) with the youngest
participant 9-years-old, and the oldest participant 12-years-old.

Table 1
Frequency Distributions of Demographic Variable (N = 35)
Variable

Frequency

Percentage

Gender
Male
Female

26
9

74.3
25.7

Age
9
10
11
12

4
5
13
13

11.4
14.3
37.1
37.1

Total Sample Ethnicity
Caucasian
Hispanic

31
4

88.6
11.4

The ADHD diagnostic categories of the participants in the study are presented in Table 2.
As can be noted, the smallest ADHD subgroup, the hyperactive subtype, comprised 11% of the
35 participants, while approximately a quarter of the participants presented with a diagnosis of
the inattentive subtype of ADHD (26%). The majority of the sample was diagnosed with ADHD
combined type (64%). Only a fraction of participants presented with a co-morbid diagnosis
(6%). Of the two participants with co-morbid diagnoses, one was diagnosed with Depressive
Disorder, NOS, while the other was diagnosed with Adjustment Disorder with Depressed mood.
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Table 2
Frequency Distributions of ADHD Profiles
Variable

Frequency

Percentage

Diagnosis
ADHD Hyperactive
ADHD Inattentive
ADHD Combined Type

4
9
22

11.4
25.7
63.9

Emotional Diagnosis
Present
Absent

2
33

5.7
94.3

Medication
MPH
Adderall
Concerta
Strattera

25
8
1
1

71.4
22.9
2.9
2.9

Dosage
5 mg
10 mg

26
9

74.3
25.7

Co-morbid diagnoses were obtained from the parents who were made aware of the additional
diagnoses by their health care provider (the first was diagnosed by a pediatrician, the second by a
master’s level mental health therapist). Also in Table 2 is found the prescribed medications used
by the participants. The most common dosage of the participant’s medication was a 5 mg dosage
(74%), while the additional participants were prescribed dosages at 10 mg (26%). These figures
represent the amount of medication taken per dose; they do not necessarily represent the total
milligrams ingested per day.
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Both male and female participants were accepted for participation, however research
shows that the prevalence of ADHD is higher in males than in females (4:1 in community
samples; 9:1 in clinical samples; Barkley, 1997b). The proportion of males to females in the
present study was approximately 3:1.
Instruments
The Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2). All
participants were administered the Wide Range Assessment of Memory and Learning Second
Edition (Sheslow & Adams, 2003).The WRAML2 is an individually administered test battery
designed to assess memory ability. It was designed to be used for clinical assessments of
memory, including evaluation of immediate and/or delay recall as well as differentiating between
verbal, visual or more global memory deficits. (Sheslow & Adams, 2003). The WRAML2
consists of six core subtests, seven delayed memory tasks, two subtests designed to assess
working memory, and four recognition memory subtests (see Figure 1). The core subtests yield
three indexes including verbal memory, visual memory, and attention/ concentration (each with a
mean of 100 and a standard deviation of 15). These three indexes combine to form the General
Memory Index.
The WRAML2 was standardized using a sample of 1,200 individuals ranging in age from
5-90 (Sheslow & Adams, 2003). The reliabilities of the three core indexes range from .85 to .93
for children between the ages of 9 to 12 years. The reliabilities of the six core subtests ranges
from .78 to .95 for children between the ages of 9 to 12 years. The reliabilities of the optional
subtests range from .72 to .96 for children between the ages of 9 to 12 years. The WRAML2
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GENERAL MEMORY
INDEX
Verbal Memory

Visual Memory

Attention/Concentration

Index
Story Memory

Index
Design Memory

Index
Finger Windows

Subtes
Verbal Learning
t
Subtes

Subtes
Picture Memory
t
Subtest

Subtes
Number/Letter
t
Subtest

Figure 1. The three core WRAML2 indexes and their contributing subtests.
t
used Cronbach’s coefficient alpha to assess the internal consistency reliabilities for all of the
subtests and indexes. The median coefficient found across the norm sample ranged from .86 to
.93, with a median of .93 for the General Memory Index. Table 3 provides the person and item
separation reliabilities for the WRAML2.
The Verbal Memory Index subtests include Story Memory and Verbal Learning. The
Story Memory subtest requires the examinee to listen to, and then recall as many parts of two
stories as can be remembered. The Verbal Learning subtest is a list-learning task. The examinee
is read a list of 16 words which is followed by an immediate free-recall trial. Three additional
list presentation/recall trials follow (Sheslow & Adams, 2003).
The Visual Memory subtests include Design Memory and Picture Memory. Design
Memory consists of five different cards with geometric designs. Each card is presented for a
five-second exposure, followed by a 10-second delay. The examinee is then asked to draw what
he/she remembers. For the Picture Memory subtest, the examinee is shown four common but
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Table 3
Person and Item Separation Reliabilities for WRAML2 Subtests
Person Separation
Reliabilities

Item Separation
Reliabilities

Core Subtest
Story Memory
Design Memory
Verbal Learning
Picture Memory
Finger Windows
Number Letter

.94
.92
.88
.85
.91
.90

.99
1.00
.99
1.00
1.00
1.00

Optional Subtest
Verbal Working Memory
Symbolic Working Memory
Sentence Memory

.85
.87
.92

.99
1.00
1.00

Delay Recall Subtests
Story Memory Delay Recall
Verbal Learning Delay Recall

.93
.73

.99
.99

Recognition Subtests
Story Memory Recognition
Design Memory Recognition
Picture Memory Recognition
Verbal Learning Recognition

.78
.56
.60
.58

.99
.99
.99
.98

visually complex scenes (e.g., a classroom) for 10 seconds. Following each scene, a similar but
alternate scene is presented and the examinee is asked to identify elements that have “been
moved, changed or added” (Sheslow & Adams, 2003).
The Attention/Concentration subtests include Finger Windows and Number-Letter. The
Finger Windows subtest requires the examinee to duplicate a demonstrated sequence of visual
locations on an 8x10 plastic card. The Number-Letter subtest requires the examinee to repeat a
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sequence of single digits and letters that are verbally presented. For both the Finger Windows
and Number-Letter subtests, the sequence to be replicated by the participant gradually becomes
longer and more challenging.
There are three optional subtests for the WRAML2. Requiring less rote memory than the
Number-Letter subtest, the Sentence Memory requires the examinee to repeat a series of longer
and longer sentences read by the examiner. On the Verbal Working Memory subtest,
participants 9-12 years of age listen to a list of words, some of which are animals and some of
which are not. Initially, participants are asked to repeat all of the words, recalling the animal
words first followed by the non-animal words in any order. The examinee is then asked to
complete a more difficult task that requires him/her to recall the animals in order of their typical
size (smallest to largest), followed by all the non-animal words in any order. Symbolic Working
Memory requires the examinee to actively manipulate information presented prior to recall, over
two levels of difficulty. For the first level, the examiner randomly dictates a series of numbers
and asks the examinee to point to the numbers dictated in correct numerical order on a stimulus
card. For the second task, a random number and letter series is dictated and the examinee is
asked to point to the dictated numbers followed by the dictated letters, each in correct order on
number and alphabet cards.
The WRAML2 also includes delayed recall and recognition subtests. Story Memory
Delay Recall requires the examinee to again recall details of the two short stories read about 15
minutes earlier in the session. The Story Memory Recognition subtest allows the examinee to
provide details of the stories using a 3-item, multiple choice format. The Verbal Learning Delay
Recall subtest requires the examinee to recall the list of words the examiner read over the four
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trials the last one of which occurred about 15 minutes earlier in the session. Thereafter, the
Verbal Learning Recognition subtest requires the examinee to respond with a “yes” or “no” to
indicate if a word read by the examiner was recognized from the original list. Design Memory
Recognition requires the examinee to respond with a “yes” or “no” when presented with
previously seen geometric shapes from the Design Memory subtest. Picture Memory
Recognition requires the examinee to respond to “yes” or “no” options on the Picture Memory
Recognition Form based on whether the examinee believes the pictured element was previously
seen on one of the four original or alternate picture stimuli used on the core Picture Memory
subtest (Sheslow & Adams, 2003). Table 4 categorizes the core, optional, delay recall, and
recognition subtests.

Table 4
WRAML2 Optional, Delay Recall, and Recognition Subtests
Core Subtests

Delayed Recall Subtests

Recognition Subtests

Story Memory

Story Memory Delay Recall

Story Memory Recognition

Verbal Learning

Verbal Learning Delay Recall

Verbal Learning Recognition

Design Memory

Design Memory Recognition

Picture Memory

Picture Memory Recognition

Optional Subtests

Finger Windows
Number-Letter
Sentence Memory
Verbal Working
Memory
Symbolic
Working Memory
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Wechsler Abbreviated Scale of Intelligence (WASI). The Wechsler Abbreviated Scale
of Intelligence (WASI; Zhu, 1999) is an abbreviated IQ measure that is composed of four
subtests and can be administered to participants ages 6-89. The subtests of the WASI include:
Vocabulary, Similarities, Block Design, and Matrix Reasoning. Scores earned on the
Vocabulary and Similarities subtests can be combined to yield a Verbal IQ; scores on the Block
Design and Matrix Reasoning subtests can be combined to yield a Non-Verbal IQ; all four
subtests combine to yield a Full Scale IQ. “The subtests were chosen for their strong association
with general cognitive abilities and for their relationship to constructs of intelligence, such as the
verbal and performance and crystallized and fluid dichotomies” (Zhu, 1999). Figure 2 shows the
four subtests of the WASI that contribute to the Estimated Full Scale IQ.

Estimated Full
Scale
Intelligence
Quotient

Vocabulary

Block Design

Similarities

Matrix
Reasoning

Figure 2. The WASI Full Scale IQ and its contributing subtests.

Effects of Medication on Memory

30

The Vocabulary subtest consists of items that are similar to the Vocabulary subtests of
the WISC-IV and the WAIS-III. For each, the examiner asked the examinee to define a word.
The Block Design subtest consist of thirteen modeled or printed patterns that the examinee must
replicate using two-colored cubes. The Similarities subtest requires the examinee to explain the
similarity between two common objects or concepts. Matrix Reasoning, involves a series of
patterns that the examinee must determine the relationship being depicted, and then choose of the
five options provided finishes the analogy (Zhu, 1999). Each of the WASI’s subtests presents
items in increasing order of difficulty and the subtest is discontinued when a ceiling rule is met.
The four subtests Cronbach’s coefficient alpha reliabilities reported on a child’s sample,
range from .86 to .93 for Vocabulary, from .81 to .91 for Similarities, from .84 to .93 for Block
Design, and from .86 to .96 for Matrix Reasoning (Ryan & Brown, 2005).
Across the 11 age groups of the children’s sample, the Cronbach’s coefficient alpha reliabilities
for the IQ scales range from .92 to .95 for both the Verbal Intelligence Quotient (VIQ) and
Performance Intelligence Quotient (PIQ), and from .95 to .97 for the FSIQ. (Zhu, 1999).
On average, the FSIQ of the WISC-III and the WASI differ by less than one point (Zhu, 1999).
Continuous Performance Test (CPT-II). The Continuous Performance Test (CPT-II;
Conners, 2000) is a vigilance task that requires the participant to remain attentive to changing
stimuli presented on a computer screen and to respond by pressing a key when specific stimuli
appear. The CPT-II is designed to be cognitively demanding and sensitive to the detection of
inattentive and impulsive symptoms of ADHD (Edwards et al., 2007). In 2003, Epstein et al.
found the CPT-II measures predicted the presence of most all of the ADHD symptoms listed by
the DSM-IV. As such, these T-scores provide an index of how deviant an individual’s score
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pattern is from a nonclinical sample, and whether the obtained results match a clinical or
nonclinical sample.
The participant’s performance is converted into a T-score. The T-score is then scored
against the CPT-II interpretation guidelines, which can be found in Table 5. The overall index
score uses discriminate functions to assess the likelihood that an examinee’s responses fit those
given by individuals with ADHD (Weis & Totten, 2004). The split-half reliability correlations
ranged between .73 and .95. The measures of CPT II had a highly satisfactory test-retest
correlation coefficient.

Table 5
Guidelines for Interpreting CPT-II T Scores and Percentiles
T Score

Percentile

Guideline

90+

Markedly atypical

60-64

85-89

Moderately atypical

55-59

70-84

Mildly atypical

45-54

31-69

Within the average range

40-44

15-30

Good performance

65+

Under 40

Under 15

Very good performance
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The standard protocol of the CPT-II test uses a short training exercise prior to the
administration of the full test to ensure that the respondent fully understands the task. After the
training exercise, the test administration is begun; it is a requirement of the standardized
procedure that an examiner remains present (Conners & MHS Staff, 2000). CPT-II respondents
are required to press a computer space bar or click a mouse whenever any letter except the letter
‘X’ appears anywhere on the computer screen. The inter-stimulus intervals (ISIs) are 1-, 2-, and
4-seconds with a display time of 250 milliseconds. The CPT paradigm is a test structure
consisting of blocks, each containing 20 trials (letter presentations). The presentation order of
the different ISIs varies between blocks (Conners & MHS Staff, 2000). The administration time
of the CPT-II is approximately 14 minutes.
Procedure
This study followed the ethical guidelines of the American Psychological Association
and approval was obtained from the Internal Review Boards (IRB) of George Fox University
before the study commenced. Thereafter, the author provided local pediatric health care
providers with flyers (Appendix B) which outlined the study and provided contact information
for the author. Parents of potential participants contacted the author by phone prior to the study
and oral consent and the initial appointment time for testing was obtained. The author then
assessed the participants’ eligibility for the study by asking each parent about their child’s
diagnoses, their prescribed medication, and reviewed the exclusionary criteria. The parent was
asked to both bring the child’s medication to the first session and have the child discontinue
his/her use of psychostimulant medication for a period of 72-hours. Parents and participants
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were informed that participation was voluntary and withdrawal may occur at any time. An
appointment time was made for the initial session of testing.
Half of the participants were randomly placed in the medication – placebo sequence and
half in the placebo – medication sequence. Consequently, there were two evaluation sessions
(i.e., Session 1 and Session 2) and the context of each can be found in Table 6. Session 2 was
scheduled for 72 hours after Session 1 to attempt to control the amount of time the medication
had been out of the participant’s system. Random sequencing was done with the assistance of an
Excel random number generator. The random number generator used the total number of
participants and randomly split them into two groups with participants in the first group being
placed in the medication-placebo sequence and the participants in the second group placed in the
placebo-medication sequence.

Table 6
Activities Associated with Each Testing Session
Session 1

Session 2

Signed consent form (parent); Collected
medication. Participant ingests medication.

Participant ingested placebo capsule in
envelope.

Parent and participant completed the ADHD
checklist.

Parent and participant provided additional
background information.

The participant completed the CPT-II.

The participant completed the CPT-II.

The participant completed half of the WASI.

The participant completed other half of the
WASI.

The participant completed half of the
WRAML2.

The participant completed other half of the
WRAML2.

Made an appointment for session two.

Child received participation prize.
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When the parent and participant arrived for Session 1, the parent provided the examiner
with a pill of the participant’s psychostimulant medication. The medication and placebo were
placed into identical opaque capsules. The placebo capsules contained gelatin. A master’s level
therapist, a separate individual from the examiner and the author, placed the medication in the
capsules and gave the child the capsule that corresponded to the treatment condition they had
randomly assigned to. The additional capsule was placed into an envelope for Session 2. This
preserved the double blind study, which requires that neither the examiner nor the participant
were aware of the medication sequence. During this time the parents were asked to read and sign
the consent form (see Appendix C). Parents and participants were informed that the participants
are joining in a study that gives the researcher information about the child’s memory. After the
parent had signed the consent form, he/she and his/her child were escorted by an examiner to a
testing room. The examiner, with the assistance of the parent, then used the ADHD symptom
checklist that is comprised of DSM-IV diagnostic criteria to confirm the child’s ADHD
diagnosis (see Appendix A). No participants were disqualified at this time as they all met the
DSM-IV diagnostic criteria, however six were disqualified during the initial phone screening
process.
After completion of the ADHD checklist, the parent was asked to sit in a waiting area
while the participant completed the assessments. The participant first completed the CPT-II.
After completion of the CPT-II the participant then completed half of the WASI (see Table 7).

Effects of Medication on Memory

35

Table 7
Content of Each WASI Subtest Groupings that was Administered on Medication and Placebo.
Test Session 1

Test Session 2

Vocabulary

Similarities

Matrix Reasoning

Block Design

The participant then completed half of the WRAML2 (see Table 8). The time from
ingestion of the medication or placebo to the completion of half of the WASI in Session 1 was
approximately 45 minutes. This gave enough time for the medication to take affect before
beginning the WRAML2.

Table 8
Content of Each of WRAML2 Subtest Groupings that was Administered on Medication Placebo.
Test Session 1

Test Session 2

Story Memory

Verbal Learning

Story Memory Recall

Verbal Learning Recall

Story Memory Recognition

Verbal Learning Recognition

Design Memory

Picture Memory

Design Memory Recognition

Picture Memory Recognition

Finger Windows

Number-Letter

Symbolic Working Memory

Working Memory

Sentences
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Upon arriving for Session 2, the participant took the remaining capsule from the
individual envelope designated from Session 1, which contained either the medication or placebo
depending on the treatment group to which the participant was assigned. After ingestion of the
capsule, the parent and participant were escorted to a testing room where the examiner collected
additional background information (e.g., age, sex, diagnostic subtype, educational level, and
dosage of medication) that was not obtained during the initial phone interview (see Appendix D).
The examiner also collected additional data concerning the participants ADHD symptomology
from both the parent and participant (see Appendix E).
The participant then completed the CPT-II for a second time. After completion of the
CPT-II, the participant completed the additional half of the WASI and the additional half of the
WRAML2. The time from ingestion of the second capsule, to completion of the WASI in
Session 2 was approximately 45 minutes. Again, this allowed time for the medication to become
active. Information on the typical ADHD medication can be found in Table 9. After the
completion of the WRAML2 in Session 2, the participant completed their participation in the
study. The participant was then given their token for participation. Tokens included two $10
gift certificates to Blockbuster, one for each session. The parents also received a $10 gas gift
card.
One doctoral student from George Fox University assisted the author in data collection.
The author and examiner administered the WRAML2 and WASI, while the author alone
administered the CPT-II to the participants on dates arranged by the author. The author and
examiner had successfully completed a course in cognitive assessment in which they received
formal training and demonstrated proficiency with the administration of the WRAML2. The
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Table 9
ADHD Medications, Half-lives, Peak Action, and Duration of Action.
Medication

Half-Life

Peak Action

Duration of Action

Adderall

1-3 hrs

1-2 hrs

4-10 hrs

Adderall XR

7-9 hrs

1-4 hrs

9 hrs

Concerta

1-3 hrs

1-3 hrs

4-8 hrs

Ritalin

1-3 hrs

1-3hrs

4-6 hrs

1.5-5 hrs

1-4 hrs

5 hrs

5 hrs

1-2 hrs

12-24 hrs

Ritalin SR
Strattera

Note: The information obtained for Table 9 was adapted from Witcher et al. (2003); Kollins
(2004); Deglin & Vallerand (2005). Adderall XR stands for extended release; Ritalin SR stands
for slow release.

author also held a review session with the assisting examiner to ensure knowledge of the
WRAML2, WASI, and the CPT-II. Both the author and the examiner scored the protocols they
administered. The scored protocols were then reviewed by the other to assess for any scoring or
tabulation errors.
Shafritz, Marchione, Gore, Shaywitz, and Shaywitz (2004) used a 72-hour period of time
during which the participant could not be on their medication before participating in their study.
They reported that, “we attempted to control for medication history by ensuring that participants
were medication-free for at least 72 hours before testing; this does not eliminate possible longterm modulation of neural functioning stemming from methylphenidate use.” Therefore, both
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sessions were scheduled after the participant had not ingested his/her medication for at least 72
hours. At the beginning of both sessions, the author asked the parent if it has been at least 72
hours since their child last ingested their psychostimulant medication.
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Chapter 3

Results

To test Hypotheses 1 through 15, a multivariate repeated measures analysis of variance
(MANOVA) was used for the 15 subtests of the WRAML2, which served as dependent
variables; session (on medication; on placebo) served as the between groups independent
variables. To test hypotheses 16-19, a separate repeated measures MANOVA was conducted
including standard scores from the four subtests of the WASI as dependent variables, and session
(on medication; on placebo) as the between group independent variables. WRAML2 subtest
performance was represented by scaled scores, with the standardization sample mean of 10 and a
standard deviation of 3. For the WASI, the subtest means are represented as T scores, with a
standardization mean of 50 and standard deviation of 10. Subtests in a domain were
counterbalanced with treatment condition, such that some participants completed specific
subtests while in the medication condition and others completed specific subtests while in
placebo condition. Please refer to the methods section for details on counterbalancing of the
conditions.
Contrary to the research hypotheses, there was no overall performance difference
between participants on medication and those on placebo for subtests of the WRAML2 (Wilks λ
= .66, F(15, 19) = .65, p > .05). Nor were there an overall difference between participants on
medication and those on placebo for the subtests of the WASI (Wilks λ = .81, F(4, 30) = 1.71, p

Effects of Medication on Memory
> .05). The analyses from the MANOVA are reported below as they relate to each of the
hypotheses. Table 10 shows the performance across both conditions for all participants..

Table 10
Performance in Medication and Placebo Conditions
Order

Mean

Std. Deviation

Effect Size

N

WRAML2 Subtests
Story Memory
Medication
Placebo
Total

9.00
9.06
9.03

1.372
1.819
1.581

Story Recall
Medication
Placebo
Total

8.83
9.24
9.03

1.543
1.715
1.618

Story Recognition
Medication
Placebo
Total

9.06
9.47
9.26

1.474
1.807
1.633

Design Memory
Medication
Placebo
Total

8.44
8.76
8.60

1.381
1.888
1.631

Design Memory Recognition
Medication
8.61
Placebo
8.82
Total
8.71

1.577
1.629
1.582

Finger Windows
Medication
Placebo
Total

1.580
1.935
1.781

7.56
8.35
7.94

-.040

18
17
35

-.250

18
17
35

-.249

18
17
35

-.194

18
17
35

-.131

18
17
35

-.447

18
17
35
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Table 10. Performance in Medication and Placebo Conditions. (Continued)
Order

Mean

Std. Deviation

Symbolic Working Memory
Medication
8.33
Placebo
8.59
Total
8.46

1.455
1.938
1.686

Sentence Memory
Medication
Placebo
Total

11.17
10.88
11.03

1.948
1.728
1.823

Verbal Learning
Medication
Placebo
Total

8.78
9.18
8.97

1.665
1.944
1.790

Verbal Learning Recall
Medication
Placebo
Total

8.72
8.76
8.74

1.565
1.300
1.421

Verbal Learning Recognition
Medication
9.11
Placebo
8.82
Total
8.97

1.568
1.510
1.524

Picture Memory
Medication
Placebo
Total

9.06
9.18
9.11

1.955
2.007
1.952

Picture Memory Recognition
Medication
8.89
Placebo
9.12
Total
9.00

1.367
1.409
1.372

Number Letter
Medication
Placebo
Total

1.801
1.345
1.579

9.22
8.94
9.09

Effect Size

N

-.151

18
17
35

.157

18
17
35

-.220

18
17
35

-.020

18
17
35

.189

18
17
35

-.061

18
17
35

-.166

18
17
35

.176

18
17
35
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Table 10. Performance in Medication and Placebo Conditions. (Continued)
Order

Mean

Std. Deviation

Verbal Working Memory
Medication
Placebo
Total

8.22
8.29
8.26

1.437
1.160
1.291

Effect Size

N

-.054

18
17
35

-.064

18
17
35

-.501

18
17
35

.051

18
17
35

-.269

18
17
35

WASI Subtest
Vocabulary
Medication
Placebo
Total

52.61
52.88
52.74

4.629
3.638
4.118

Matrix Reasoning
Medication
Placebo
Total

52.06
54.35
53.17

5.116
3.952
4.668

Similarities
Medication
Placebo
Total

52.17
51.94
52.06

4.926
4.100
4.478

Block Design
Medication
Placebo
Total

52.39
53.53
52.94

4.002
4.460
4.207

Note: WRAML2 = Wide Range Assessment of Memory and Learning, 2nd Edition. WASI =
Wechsler Abbreviated Intelligence Scale.

Hypotheses
Hypothesis 1. Participants diagnosed with ADHD will score higher on the Story Memory
subtest of the WRAML2 in the psychostimulant medication condition than when they are in the
placebo condition.
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There were no significant differences evidenced across treatment conditions for Story
Memory, (F(1, 33) = .01, p > .05). Contrary to the hypothesis, Story Memory performance was
non-significant for psychostimulant medication and placebo conditions.
Hypothesis 2. Participants diagnosed with ADHD will score higher on the Story Memory
Recall subtest of the WRAML2 in the psychostimulant medication condition than when they are
in the placebo condition.
There were no significant differences evidenced across treatment conditions for the Story
Memory Recall subtest, (F(1, 33) = .53, p >.05). Contrary to the hypothesis, Story Memory
Recall performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 3. Participants diagnosed with ADHD will score higher on the Story Memory
Recognition subtest of the WRAML2 in the psychostimulant medication condition than when
they are in the placebo condition.
There were no significant differences evidenced across treatment conditions for the Story
Memory Recognition subtest, (F(1, 33) = .56, p >.05). Contrary to the hypothesis, Story
Memory Recognition performance was non-significant for psychostimulant medication and
placebo conditions.
Hypothesis 4. Participants diagnosed with ADHD will score higher on the Design
Memory subtest of the WRAML2 in the psychostimulant medication condition than when they
are in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Design Memory subtest, (F(1, 33) = .33, p >.05). Contrary to the hypothesis, Design Memory
performance was non-significant for psychostimulant medication and placebo conditions.
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Hypothesis 5. Participants diagnosed with ADHD will score higher on the Design
Memory Recognition subtest of the WRAML2 in the psychostimulant medication condition than
when they are in the placebo condition.
There were no significant differences evidenced across treatment conditions for Design
Memory Recognition subtest, (F(1, 33) = .15, p >.05). Contrary to the hypothesis, Design
Memory Recognition performance was non-significant for psychostimulant medication and
placebo conditions.
Hypothesis 6. Participants diagnosed with ADHD will score higher on the Verbal
Learning subtest of the WRAML2 in the psychostimulant medication condition than when they
are in the placebo condition.
There were no significant differences evidenced across treatment conditions for Verbal
Learning subtest, (F(1, 33) = .43, p >.05). Contrary to the hypothesis, Verbal Learning
performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 7. Participants diagnosed with ADHD will score higher on the Verbal
Learning Recall subtest of the WRAML2 in the psychostimulant medication condition than when
they are in the placebo condition.
There were no significant differences evidenced across treatment conditions for Verbal
Learning Recall subtest, (F(1, 33) = .01, p >.05). Contrary to the hypothesis, Verbal Learning
Recall performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 8. Participants diagnosed with ADHD will score higher on the Verbal
Learning Recognition subtest of the WRAML2 in the psychostimulant medication condition than
when they are in the placebo condition.
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There were no significant differences evidenced across treatment conditions for Verbal
Learning Recognition subtest, (F(1, 33) = .31, p >.05). Contrary to the hypothesis, Verbal
Learning Recognition performance was non-significant for psychostimulant medication and
placebo conditions.
Hypothesis 9. Participants diagnosed with ADHD will score higher on the Picture
Memory subtest of the WRAML2 in the psychostimulant medication condition than when they
are in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Picture Memory subtest, (F(1, 33) = .03, p >.05). Contrary to the hypothesis, Picture Memory
performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 10. Participants diagnosed with ADHD will score higher on the Picture
Memory Recognition subtest of the WRAML2 in the psychostimulant medication condition than
when they are in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Picture Memory Recognition subtest, (F(1, 33) = .24, p >.05). Contrary to the hypothesis,
Picture Memory Recognition performance was non-significant for psychostimulant medication
and placebo conditions.
Hypothesis 11. Participants diagnosed with ADHD will score higher on the Finger
Windows subtest of the WRAML2 in the psychostimulant medication condition than when they
are in the placebo condition.
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There were no significant differences evidenced across treatment conditions for the
Finger Windows subtest, (F(1, 33) = 1.79, p >.05). Contrary to the hypothesis, Finger Windows
performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 12. Participants diagnosed with ADHD will score higher on the Number
Letter subtest of the WRAML2 in the psychostimulant medication condition than when they are
in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Number Letter subtest, (F(1, 33) = .27, p >.05). Contrary to the hypothesis, Number Letter
performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 13. Participants diagnosed with ADHD will score higher on the Symbolic
Working Memory subtest of the WRAML2 in the psychostimulant medication condition than
when they are in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Symbolic Working Memory subtest, (F(1, 33) = .20, p >.05). Contrary to the hypothesis,
Symbolic Working Memory performance was non-significant for psychostimulant medication
and placebo conditions.
Hypothesis 14. Participants diagnosed with ADHD will score higher on the Verbal
Working Memory subtest of the WRAML2 in the psychostimulant medication condition than
when they are in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Verbal Working Memory subtest, (F(1, 33) = .03, p >.05). Contrary to the hypothesis, Verbal
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Working Memory performance was non-significant for psychostimulant medication and placebo
conditions.
Hypothesis 15. Participants diagnosed with ADHD will score higher on the Sentence
Memory subtest of the WRAML2 in the psychostimulant medication condition than when they
are in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Sentence Memory subtest, (F(1, 33) = .21, p >.05). Contrary to the hypothesis, Sentence
Memory performance was non-significant for psychostimulant medication and placebo
conditions.
Hypothesis 16. Participants diagnosed with ADHD will score higher on the Vocabulary
subtest of the WASI in the psychostimulant medication condition than when they are in the
placebo condition.
There were no significant differences evidenced across treatment conditions for the
Vocabulary subtest, (F(1, 33) = .037, p >.05). Contrary to the hypothesis, Vocabulary
performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 17. Participants diagnosed with ADHD will score higher on the Matrix
Reasoning subtest of the WASI in the psychostimulant medication condition than when they are
in the placebo condition.
There were no significant differences evidenced across treatment conditions for the
Matrix Reasoning subtest, (F(1, 33) = 2.2, p >.05). Contrary to the hypothesis, Matrix
Reasoning performance was non-significant for psychostimulant medication and placebo
conditions.
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Hypothesis 18. Participants diagnosed with ADHD will score higher on the Similarities
subtest of the WASI in the psychostimulant medication condition than when they are in the
placebo condition.
There were no significant differences evidenced across treatment conditions for the
Similarities subtest, (F(1, 33) = .02, p >.05). Contrary to the hypothesis, Similarities
performance was non-significant for psychostimulant medication and placebo conditions.
Hypothesis 19. Participants diagnosed with ADHD will score higher on the Block
Design subtest of the WASI in the psychostimulant medication condition than when they are in
the placebo condition.
There were no significant differences evidenced across treatment conditions for the Block
Design subtest, (F(1, 33) = .64, p >.05). Contrary to the hypothesis, Block Design performance
was non-significant for psychostimulant medication and placebo conditions.
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Chapter 4

Discussion

The present study was an investigation to assess if the use of psychostimulant medication
would result in higher scores on measures of memory and intelligence among participants with
ADHD. The results of the analyses showed that psychostimulant medication did not
significantly alter performance on measures of verbal or visual memory, nor on verbal or visual
measures of intelligence compared to placebo conditions.
In the current study, the medicated ADHD children were receiving an individually
prescribed dose of stimulant medication. Previous research has found that improvements in
cognitive functioning are seen in a dose-dependent linear curve (i.e., low doses effect cognitive
aspects more significantly than higher doses (2.5-5; Hoeppner et al., 1997). It could be argued
that medication dose influenced performance in this study (i.e., if the dosages were too high to
effect cognitive processes and solely treated behavior symptoms; Kempton, 1999). The present
study utilized varied dosages (both 5 and 10 mg) along with various types of prescribed
medications. It is possible that by not examining one specific type and/or dosage of
psychostimulant medication the study was impacted in unknown ways.
A subjective scale was provided for parents (see Appendix D) to rate their children on
different areas including: the child’s overall behavior (1 = very poor to 10 = very good), the
child’s level of distractibility (1 = not distractible to 10 = very distractible), the child’s activity
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level (1 = not active to 10 = very active), and the parent’s perception on the effects of their
child’s medication (1 = not effective to 10 = very effective). Means for the parent ratings were as
followed: Behavior (mean: 6.5; sd = 1.42); Distractibility (mean: 7.8; sd = 1.65); Activity level
(mean: 7.2; sd = 1.57); Effect of medication (mean: 7.0; sd = 1.53). Per the parent’s report, it
appears that the psychostimulant medication has been moderately effective in treating their
children’s symptoms of distractibility and hyperactivity. While the medication seems to be
addressing the behavioral concerns of the children’s ADHD symptoms, it seems to be doing little
to help memory or IQ processes as research indicates that cognitive processes are often found
helpful at low doses (2.5 - 5 mg; Pliszka et al., 2006).
The current study found that results of 12 of the 14 subtests of the WRAML2 and 3 of the
4 subtests of the WASI were higher in the placebo condition. Of the 19 subtest procedures
utilized, 15 (78.95%) had lower levels of performance associated with the medication condition.
While some of the 15 subtests differences were small, and none statistically significant,
nonetheless, when subhected to a chi-square analysis, the number of subtests with lower
medication performance across the 19 subtests was found to be greater than would be expected
by chance (χ2(1) = 8.78, p < .01). Therefore, there is a trend suggested that medication is not
helpful, and might, in fact, even be subtly antagonistic to recall.
While most of the CPT-II data were lost, data pertaining to Table 5 were salvageable.
This data suggest that, according to the CPT-II ADHD symptom severity scores, the participants
in the study fell within the average range of ADHD symptom severity. The participants in the
medication condition for Session 1 yielded a mean CPT-II symptom severity score of 51.31 (sd =
8.04); while the placebo condition for Session 1 yielded a mean of 51.94 (sd = 8.11). Likewise
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the results of medication condition for Session 2 yielded a mean CPT-II symptom severity score
of 50.42 (sd = 8.17); while the placebo condition for Session 2 yielded a mean of 54.99 (sd =
6.79). It could be argued that while the participants met clinical criteria for ADHD their level of
symptom severity was minimal and therefore the results were muted due to the lack of severe
clinical symptomology within the participant pool. It may also be argued that the participants,
according to the CPT-II, did not meet DSM-IV diagnostic criteria for ADHD.
Swanson (1993) conducted a comprehensive examination of 341 reviews of the effects of
stimulant medication on children with ADHD. His review found that psychostimulant
medication was ineffective for 25 to 40 percent of children with ADHD in terms of behavioral
improvements. Additionally, there was no evidence of significant improvement in reading,
athletic or game skills, proactive social skills, learning and achievement other than improved
attending. If the reviewed research indicated no changes in behavioral symptoms for up to 40%
of participants, then it is likely that a much higher percentage of participants experienced no
effects, or even negative effects, on cognitive components. “Inconsistent MPH-achievement
findings may be in part due to differences in cognitive and behavioral dose-response
relationships. When differential MPH dose-response relationships have been reported, lower
doses typically improve academic behavior, with little or no additional benefit found for higher
doses” (Hale et al., 2011).
Barkley et al., (2000) stated that it is extremely difficult to evaluate drug response in an
outpatient setting. “[An outpatient setting] will compromise the clinician’s abilities to
systematically evaluate actual drug responding, thereby undermining clinical judgments of drug
and dose effectiveness.” Similar to the results described above, at the group level Barkley et al.,
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(2000) found no response to medication per attention and inhibition in varied dosages in an
outpatient research setting.
Stimulants have been the mainstay of psychopharmacologic treatment of ADHD for over
fifty years. Methylphenidate is the most frequently prescribed stimulant (Goldman et al., 1998).
While research continues to support the notion that psychostimulant medication improves
behavioral characteristics (Barkley, 2004), the research is still unclear how effective
psychostimulant medication is for aspects of memory such as sustained attention, encoding,
retention, or recognition. The present study would suggest that psychostimulant medication has
no demonstrable effects on children’s performance on short term and delayed memory tasks.
Limitations
The CPT-II was used as an additional diagnostic measure to Appendixes A & E.
However, it should be noted that the computer on which the CPT-II data was stored, crashed
rendering the data inaccessible. This limited the amount of data that could be utilized from the
CPT-II.
The data that were retrieved from the CPT-II suggested that the severity of the
symptomology of the participants was within the average range. This appeared to limit the
results as it is probable that participants with more severe clinical presentation may have gained
more cognitive benefit from psychostimulant medication than participants with severity of
symptoms in the average range.
The study also included all three diagnostic subtypes of ADHD, as well as several
different medications and two different doses. Perhaps examining one specific diagnostic
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subtype, one specific type of medication, or one specific dose of medication may have yielded
different results.
Future Direction
It will be important for future research in this area to focus on each specific subtype of
ADHD, to determine which, if any, may be more sensitive medication effects. The present study
had a limited number of ADHD inattentive and hyperactive subtypes. Future studies examining
medication effects on each of the three subtypes would be beneficial.
Research utilizing specific dosing standards, as well as specific medication types, would
allow for medication effects on intellectual and memory processes to be examined more closely
as there is ongoing debate in the research about which dosage of which medication yields more
reliable results for both behavior and cognition (Hoeppner et al., 1997). Studies which
investigate medication doses below recommended, at recommended, and higher than
recommended doses for the three or four most commonly used medications would be greatly
beneficial.
Memory retrieval and executive functioning are closely related. Future research
integrating memory and executive functioning measures may created a more well rounded
picture of medication effects on memory functioning and related executive functioning skills
such as working memory, recall, and inhibition.
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ADHD Questionnaire

Inattention: Six (or more) of the following symptoms must have persisted for at least 6 months to
a degree that is maladaptive and inconsistent with developmental level:
_____ Fails to give attention to details or makes careless mistakes in schoolwork, chores or
other activities
_____ Has difficulties sustaining attention in tasks or play activities
_____ Does not seem to listen when spoken to directly
_____ Does not follow through on instructions and fails to finish schoolwork, chores, or duties
in the home (not due to oppositional behavior or failure to understand directions)
_____ Has difficulty organizing tasks and activities
_____ Avoids or strongly dislikes tasks that require sustained mental effort (such as schoolwork
or homework)
_____ Loses things necessary for tasks or activities (such as school assignments, pencils, books,
or toys)
_____ Easily distracted by extraneous stimuli
_____ Forgetful in daily activities
Hyperactivity-Impulsivity: Six (or more) of the following symptoms must have persisted for at
least six months to a degree that is maladaptive and inconsistent with developmental level:
_____ Fidgets with hands or feet or squirms in seat
_____ Leaves seat in classroom or in other situations in which remaining in seat is expected
(such as the dinner table)
_____ Runs about or climbs excessively in situations where it is inappropriate (in adolescents
this may be limited to a subjective feeling of restlessness)
_____ Has difficulty playing or engaging in leisure or play activities quietly
_____ Is “on the go” or acts as if “driven by a motor”
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_____ Talks excessively
_____ Blurts out answers to questions before the questions have been completed
_____ Has difficulty waiting in lines or awaiting turn in games or group situations
_____ Interrupts or intrudes on others (such as butting into conversations or other activities)
Additional Diagnostic Criteria
_____ Some hyperactive-impulsive or inattentive symptoms that caused impairment were
present before age 7.
_____ Some impairment from the symptoms is present in two or more settings.
_____ There must be clear evidence of clinically significant impairment in social, academic, or
occupations functioning.
_____ The symptoms do not occur exclusively during the course of a Pervasive Developmental
Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by another
mental disorder.
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$20 GIFT CARD OPPORTUNITY!!
What: A study on memory and the effects that psychostimulant medication has on the
memory of children with Attention Deficit/Hyperactivity Disorder (ADHD). As a
token “Thank you”, each child will receive a $20 gift certificate to Blockbuster
Video for his/her participation. The parent will also receive a $10 gas card for
their time and effort transporting their children.
Who: Participants will be children between the ages of 9-12 who have been diagnosed
with ADHD and are taking medication to control these symptoms. Children will
be asked to complete a brief IQ assessment and a memory assessment, both of
which will be divided between the 2 sessions. They will also do a computerized
assessment that is much like a computer game. Session 1 will be approximately an
hour, and session 2 will only take about 40 minutes. Participation is completely
voluntary and may stop at any time
Where: All tasks will be administered by a trained doctoral psychology student at the
Tigard High School Health Center.
Why: The results may help children with this condition, and their families, to be better
informed about the effects stimulant medication has on memory in children with
ADHD.
When: Assessments will be conducted at your convenience!

I hope that you and your child will be able to help with this project. To schedule your
sessions, please contact Ben Dunagan at (503)333-7072 or email at
bdunagan05@georgefox.edu by May 15th. I look forward to working with you and your
child.
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Consent Form
I understand that my child is a willing participants in this doctoral research investigating
the effects of psychostimulant medication on the memory of children with ADHD. As a
part of this study, my child will be asked to complete a cognitive assessment and a
memory assessment, supply information about my child’s ADHD symptoms and
diagnosis, and be willing to have my child assessed both on and off of his/her prescribed
medication. These assessments will be completed over two sessions.
I understand that myself, and my child will have the opportunity to take part in a
discussion with the person administering the assessments regarding the procedures
involved. I understand that myself and my child will be able to receive a summary of the
study’s results.
I understand that my child may stop his/her involvement at any point, with no
explanation necessary.
If I have any questions that the person administering these tests cannot answer or
concerns about the testing process, I can contact Ben Dunagan, MA. Mr. Dunagan is
being supervised by Dr. Wayne Adams of George Fox University. Mr. Dunagan is
available at 503-333-7072 or by email at: bdunagan05@georgefox.edu.
_____________________________
Printed Participant’s Name

______________________________
Participant’s Signature

_____________________________
Printed Parent’s Name

______________________________
Parent’s Signature

____________________________________
Ben Dunagan, MS Ed., MA

Date:_____/_____/_______

___________________________
Test Examiner’s Signature
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Background Information
Participant ID # ____________________________
Examiner: _________________________________
Child’s Name: ___________________________________________________________
First
Middle
Last
Date of Birth: ______/______/_______
Sex (circle one please): Male

Age: ___________
Female

Ethnicity (circle one please): Caucasian
African American
Other: ______________________

Asian

Hispanic

Grade (last grade passed): ___________________
Parents’ Names: __________________________________________________________
Contact Information
What is the best way to contact you? (circle one please):
Phone Number: ___________________

Phone

Email

Email: ________________________

Home Address: ___________________________________________________________
*Note: Contact information is used ONLY for scheduling appointments and will NOT be
used in the research.
Child’s Diagnosis: ________________________________________________________
Age of Diagnosis: ____________

Profession that Diagnosed: ___________________

Medication(s): ___________________________________________________________
Dosage(s): ______________________________________________________________
Side Effect(s): ___________________________________________________________
Allergic to milk?

Yes

No

Does your child have vision or hearing difficulties?

Yes

No

If yes, explain: ___________________________________________________________

Effects of Medication on Memory
1st Appointment: _________________________________________________
2nd Appointment: _________________________________________________
Has it been 72 hours since your child ingested his/her psychostimulant medication?
Yes

No

Parent Ratings
How is your child’s behavior overall?
1

2

3

4

5

6

7

8

9

10

6

7

8

9

10

6

7

8

9

10

9

10

How is your child’s distractibility?
1

2

3

4

5

How is your child’s activity level?
1

2

3

4

5

How has the medication affected your child’s behavior?
1

2

3

4

5

6

7

8
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Attention Deficit/Hyperactivity Disorder (ADHD)
Participant History
At what age did you first notice inattentive or hyperactive symptoms?
________________________________________________________________________
At what age was he/she diagnosed with ADHD?
________________________________________________________________________
Where, and by whom, was he/she diagnosed?
________________________________________________________________________
Has your child ever been diagnosed with an emotional or behavioral problem other than
ADHD?
Yes
No
If yes, please describe: _____________________________________________________
________________________________________________________________________
At what age was he/she diagnosed? ___________________________________________
Where, and by whom, was he/she diagnosed?
________________________________________________________________________
Is this a current diagnosis?

Yes

No
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Benjamin Dunagan, PsyD.
9177 E. 35th Ave., Denver, CO 80238
(303) 570-5190
bdunagan09@gmail.com
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May 2011

Doctorate (PsyD.)
George Fox University
Graduate Department of Clinical Psychology
Newberg, OR, APA Accredited

May 2007

Master of Arts: Clinical Psychology
George Fox University
Graduate Department of Clinical Psychology
Newberg, OR, APA Accredited

Dec. 2004

Master of Science: Community Counseling
University of Nebraska at Kearney
Kearney, NE, CACREP Accredited

May 2002

Bachelor of Science: Psychology; Minor in Sociology
Nebraska Wesleyan University
Lincoln, NE

Licensure
Oct. 2010 – Aug. 2011

Licensed Professional Counselor – State of Colorado
 License number - 5878

Clinical Experience
Jan. 2011 – Current

Kaiser Permanente
Denver, CO
Emphasis: Health Psychology
Responsibilities:
 Provide personality and diagnostic psychological
assessments.
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July 2009 – June 2010

Aug. 2008 – June 2009

80

Provide in-takes and individual psychotherapy with
heavy caseload.
Interdisciplinary work environment.

Internship (APA Accredited)
Jersey Shore University Medical Center
Neptune, NJ
Emphasis: Primary Care Psychology, Behavioral Pain
Management, & Medical Issues
Rotations:
Consultation and Liaison
 Consultation and evaluations with a variety of medical
and psychological diagnoses including substance abuse.
 Comprehensive psychological assessments on inpatient
psychiatric unit with co-morbid medical issues.
Behavioral Medicine
 Primary care psychology including post partum
depression evaluations.
 Provided pain management interventions in conjunction
with physicians at musculoskeletal clinic. Discussed
rationale for pain medication treatment and
prescriptions.
 Interventions included progressive muscle relaxation,
diaphragmatic breathing, sleep management, cuecontrolled relaxation, stress management, & CBT for
pain management.
Inpatient Treatment
 Provided group and individual therapy for patients with
SMPI, eating disorders, and other chronic conditions.
 Provided outpatient referrals and recommendations.
Neuropsychological Assessment
 Neuropsychological assessment with acute medical
patients on rehabilitation unit.
 Patient presentations included stroke, toxic/metabolic or
anoxic encephalopathy, neurosurgical interventions for
malignant neuroplastic disease or hydrocephalus shunt
placement, traumatic brain injury, cardiac crisis, multiple
sclerosis, dementia, spinal cord surgery and general
debility due to multiple & coexisting medical conditions.
Outpatient Clinic
 Outpatient psychotherapy with adults and adolescents.
 Co-facilitated group: Coping with Chronic Medical
Conditions.
Pre-Internship
Kaiser Permanente
Portland, OR
Population: Adult, Adolescent, & Children Outpatient
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Emphasis: Neuropsychological Assessment & Primary Care
Psychology
Responsibilities:
 Provided weekly outpatient neuropsychological
assessments for patients with both chronic and acute
medical issues.
 Provided personality and diagnostic psychological
assessments.
 Provided in-takes and individual psychotherapy with
heavy caseload.
 Interdisciplinary work environment.
Supervisor: Ron Sandoval, PhD.
Aug. 2007 – June 2008

Practicum II
Oregon State Hospital
Salem, OR
Population: Adult Inpatient
Emphasis: Neuropsychological & Cognitive Assessment with
SPMI
Responsibilities:
 Provided weekly cognitive assessments.
 Provided bi-weekly neuropsychological assessments for
patients dealing with chronic medical problems.
 Presented at the Neuropsychological Grand Rounds:
“Neuropsychological Functioning of Patient with
Multiple Myeloma and Renal Failure”
 Interdisciplinary work environment.
Supervisor: James Clay, PsyD.

Aug. 2006 – Aug. 2007

Practicum I
Lifeworks Northwest: Cedar Mill & Tigard sites
Portland & Tigard, OR
Population: Adult Outpatient
Emphasis: Individual Psychotherapy
Responsibilities:
 Provided individual psychotherapy to patients presenting
with a variety of diagnoses. Heavy case load.
 Conducted in-take interviews, provided diagnosis, and
treatment planning.
 Treated diverse clientele and diagnostic issues.
 Offered a paid position at the end of the practicum.
Supervisor: Ken Ihli, PhD.

Jan. 2006 – April 2006

Pre-Practicum training: GFU Counseling Center
George Fox University, Newberg, OR
Population: Adult Outpatient
Emphasis: Individual Psychotherapy
Responsibilities:
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Provided individual psychotherapy with university
students.
 Conducted in-take interviews, treatment planning,
mental status, and goal setting.
 Completed case presentations to supervision group.
Supervisor: Sally Hopkins, PsyD.
July 2004 – Dec. 2004

Masters Level Internship: Richard Young Hospital
Kearney, NE
Population: Inpatient adolescents
Emphasis: Individual, Group, & Family Psychotherapy
Responsibilities:
 Provided individual, group, and family psychotherapy.
 Responsible for treatment planning and case notes.
 Work closely with the child psychiatrist.
 Interdisciplinary work environment.
Supervisor: Kathleen Shundoff, PhD.

Jan. 2004 – May 2004

Masters Practicum: University of Nebraska at Kearney
Counseling Center
Kearney, NE
Population: Adults, Adolescents, and Children
Emphasis: Individual Psychotherapy
Responsibilities:
 Provided individual psychotherapy.
 Responsible for treatment planning and case notes.
 Regular case presentations to supervision group.
Supervisor: David Hof, PhD. Ed.

May 2002 – Oct. 2003

St. Francis Hospital Alcohol and Drug Treatment Center
Grand Island, NE
Population: Adults and Adolescents
Emphasis: Substance Abuse
Responsibilities:
 Worked with clients with substance abuse issues.
 Supervised client’s daily activities.
 Co-facilitated group therapy.

Jan. 2001 – May 2002

Undergraduate Practicum: Center Point Treatment Center
Lincoln, NE
Population: Adolescents
Emphasis: Substance Abuse
Responsibilities:
 Worked with adolescents who were inpatient substance
abuse treatment center.
 Co-facilitated substance abuse and eating disorders
group therapy.
 Observed individual and group therapy.

Effects of Medication on Memory

83

Supervisor: Bill McNeil, PhD.
Jan. 2000 – May 2001

Undergraduate Practicum: Northwest Family Center
Lincoln, NE
Population: Adolescents
Emphasis: Adolescent Social Skills
Responsibilities:
 Worked with adolescents who had sexual abuse history.
 Facilitated involvement in social activities.
 Monitored progress concerning school work.
Supervisor: Bill McNeil, PhD.
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